CJC-1295 with DAC

CJC-1295 with DAC is an investigational, long-acting synthetic analogue of growth hormone-releasing hormone (GHRH), the natural hormone that stimulates growth hormone (GH) release from the pituitary gland. It contains a modified GHRH peptide sequence combined with a Drug Affinity Complex (DAC), an albumin-binding chemical group that substantially extends the peptide’s circulation time. Unlike shorter-acting GHRH analogues, CJC-1295 with DAC remains biologically active for several days following administration, allowing prolonged stimulation of the growth hormone and insulin-like growth factor 1 (IGF-1) signaling system.

Early human clinical trials demonstrated sustained increases in growth hormone and IGF-1 concentrations, providing direct evidence that CJC-1295 with DAC activates the GH/IGF-1 axis. Researchers have investigated its potential applications in growth hormone deficiency, body composition, metabolic regulation, and other conditions associated with altered GH secretion. However, the clinical studies primarily measured hormone concentrations rather than improvements in muscle growth, fat reduction, sleep, recovery, or longevity. A subsequent Phase 2 trial in HIV-associated visceral obesity was terminated without published efficacy results. CJC-1295 with DAC remains investigational, is not FDA-approved, and has an incompletely characterized long-term safety profile.

CJC-1295 with DAC is a long-acting GHRH analogue that binds circulating albumin to produce sustained growth hormone and IGF-1 signaling. Early human trials demonstrated substantial hormone increases lasting several days, but benefits for fat loss, muscle growth, recovery, and longevity remain unproven, and long-term safety is uncertain.

CJC-1295 with DAC stimulates the body's growth hormone axis by activating pituitary GHRH receptors. Its albumin-binding modification allows extended circulation and prolonged endocrine activity compared with native GHRH and short-acting Modified GRF 1-29.

1. GHRH Receptor Activation

• Natural GHRH is released by the hypothalamus and stimulates growth hormone secretion from the anterior pituitary gland.
• CJC-1295 activates GHRH receptors located on pituitary somatotroph cells.
• Receptor activation stimulates intracellular cAMP signaling and promotes endogenous GH release.
• The response depends on functioning pituitary cells and the body's endocrine feedback mechanisms.

2. Drug Affinity Complex and Albumin Binding

• The DAC modification contains a reactive chemical group designed to form a covalent bond with serum albumin.
• Albumin is a circulating blood protein that helps transport numerous biological substances.
• Albumin attachment substantially slows peptide clearance and extends systemic exposure.
• Human clinical trials measured a terminal elimination half-life of approximately 5.8–8.1 days.

3. Sustained Growth Hormone Secretion

• In human studies, a single administration increased mean GH concentrations for six days or longer.
• Mean GH increases ranged approximately two- to ten-fold across the studied doses.
• The extended activity differs substantially from the short receptor exposure expected with Modified GRF 1-29.

4. IGF-1 Production

• Growth hormone stimulates the production of insulin-like growth factor 1, particularly in the liver.
• IGF-1 participates in growth-related signaling, tissue metabolism, and cellular maintenance.
• Clinical studies demonstrated approximately 1.5- to three-fold increases in mean IGF-1 concentrations after a single administration.
• Increased IGF-1 persisted approximately nine to eleven days in the initial human trials.

5. Preserved Growth Hormone Pulsatility

• Growth hormone is normally secreted in pulses throughout the day and night.
• A 2006 human study found that GH pulsatility remained detectable after CJC-1295 treatment.
• Pulse frequency and magnitude were not significantly altered in that study.
• However, baseline or trough GH concentrations increased substantially, indicating a higher overall hormonal exposure.

6. Repeated Exposure and Hormonal Accumulation

• Because CJC-1295 remains in circulation for several days, repeated administration can create overlapping exposure.
• Human studies demonstrated sustained IGF-1 elevation following repeated doses.
• Researchers observed evidence of cumulative endocrine effects.
• Long-term effects on feedback regulation, receptor responsiveness, and metabolic health remain uncertain.

The Key Difference: CJC-1295 with DAC is not simply a longer-lasting version of an otherwise identical dosing schedule. Albumin binding changes its pharmacokinetics substantially, producing prolonged GH/IGF-1 stimulation. Natural GH pulses may persist, but overall baseline hormone exposure can remain elevated.

CJC-1295 with DAC has demonstrated measurable endocrine activity in human clinical research. However, the most reliable findings concern hormone concentrations rather than clinical improvements in body composition, muscle growth, recovery, or longevity.

• Sustained Growth Hormone Elevation: A Phase 1 study demonstrated approximately two- to ten-fold increases in mean GH concentrations lasting six days or longer after a single administration.
• Increased IGF-1: Mean IGF-1 concentrations increased approximately 1.5- to three-fold and remained elevated for nine to eleven days.
• Long-Acting Pharmacokinetics: The measured half-life ranged from 5.8 to 8.1 days.
• Preserved GH Pulsatility: A separate human study demonstrated that GH pulses persisted during prolonged receptor stimulation.
• Higher Baseline GH: The pulsatility study reported a 7.5-fold increase in basal GH levels and a 46% increase in mean overnight GH levels.
• IGF-1 Response: The same study observed approximately 45% higher IGF-1 levels one week after administration.
• Potential Fat Metabolism: Growth hormone promotes lipolysis, but clinically meaningful fat loss from CJC-1295 with DAC has not been established.
• Potential Lean Tissue Effects: GH/IGF-1 signaling influences tissue metabolism, but increased muscle mass or strength has not been demonstrated in controlled CJC-1295 trials.
• Potential Tissue Repair: The hormonal mechanism provides a rationale for research, but accelerated healing of tendons, ligaments, or muscles remains unproven.
• Potential Sleep Effects: GH physiology is related to sleep, but no controlled study has demonstrated better sleep quality from this compound.

Notable Phase 1 Finding: Two randomized, double-blind, placebo-controlled studies published in 2006 evaluated the pharmacokinetics and hormonal effects of CJC-1295 in healthy adults. The peptide produced sustained increases in GH and IGF-1, with a measured half-life of approximately one week.

Notable Pulsatility Finding: In a separate study of healthy men, CJC-1295 preserved the frequency and amplitude of growth hormone pulses while markedly increasing baseline GH concentrations.

Phase 2 Research Limitation: A study investigating CJC-1295 for HIV-associated visceral obesity was terminated before generating published efficacy results. Therefore, no reliable treatment-related reduction in visceral fat can be claimed from that trial.

Human Clinical Limitation: The available studies do not demonstrate that CJC-1295 with DAC increases muscle strength, prevents age-related muscle loss, reduces abdominal fat, improves sleep, accelerates injury recovery, or extends lifespan.

Research Perspective: CJC-1295 with DAC has substantially stronger direct evidence of GH-axis activation than the no-DAC formulation. However, its ability to produce meaningful therapeutic benefits remains unproven.

CJC-1295 with DAC has been administered subcutaneously in human clinical trials investigating growth hormone and IGF-1 secretion. Unlike CJC-1295 without DAC, published human dose-ranging studies exist for this compound. However, those studies were short and focused primarily on endocrine responses rather than establishing a therapeutic dose for body composition, recovery, or longevity.

Published Clinical and Community-Reported Dosing

Clinical Research Dose Interpretation

• Single-Dose Trials: The initial study evaluated several weight-based amounts to characterize hormone responses, drug exposure, and tolerability.
• Repeated-Dose Trials: Researchers evaluated weekly and every-two-week administration to examine accumulation and sustained IGF-1 activity.
• Hormone Response: In the initial trial, doses of 30 and 60 mcg/kg were described as relatively well tolerated, but this does not establish them as safe long-term therapeutic doses.
• Higher Exposure: Higher trial doses generally produced more frequent or pronounced adverse events.

Administration Considerations:

• Subcutaneous Administration: The route used in published human studies.
• Frequency: Human studies investigated weekly and every-two-week administration. Neither schedule is an approved treatment regimen.
• Albumin Binding: The measured 5.8–8.1-day half-life means repeated exposure can accumulate over time.
• Fasting: Community routines sometimes recommend fasting around administration, but specific fasting windows have not been validated in clinical trials.
• Bedtime Administration: No human clinical evidence demonstrates that bedtime administration produces better outcomes.
• Injection Location: Claims that administration near a particular muscle or injury produces targeted benefits have not been established.
• Reconstitution: No FDA-approved consumer formulation, universal mixing procedure, or validated home-storage period exists for research-market CJC-1295 with DAC.
• Product Identity: Commercial products may inconsistently distinguish DAC and no-DAC versions. Accurate molecular identification is essential because their expected durations differ substantially.

Important Distinction: The clinical trial amounts were calculated by body weight and administered under medical supervision. Community fixed-milligram schedules are not equivalent to a validated clinical treatment protocol.

Research Perspective: The published dosing amounts provide useful evidence of endocrine activity and short-term tolerability. Community schedules are included for comparison, not as recommended treatment doses. No safe and effective long-term human dosing regimen has been established.

No clinically validated long-term treatment cycle exists for CJC-1295 with DAC. Published human studies evaluated relatively short periods of exposure, while community protocols commonly describe eight to sixteen weeks of administration followed by a break.

• Phase 1 Single-Dose Research: Evaluated endocrine responses during a 28-day study period.
• Phase 1 Repeated-Dose Research: Evaluated two or three administrations during a 49-day study period.
• GH Pulsatility Study: Compared growth hormone secretion before treatment and one week after a single dose.
• Phase 2 Research: A 12-week treatment study was planned in adults with HIV-associated visceral obesity, but the trial was terminated.
• Community Short Cycles: Six to eight weeks are sometimes described.
• Community Standard Cycles: Eight to twelve weeks are frequently discussed.
• Community Extended Cycles: Some informal protocols describe twelve to sixteen weeks or longer.
• Washout Periods: Four to eight weeks, and sometimes longer, are discussed informally, but no clinically validated washout schedule exists.
• Long-Term Exposure: The effects of repeated cycles over months or years have not been adequately evaluated.

Research Consideration: Because the peptide remains active for approximately one week, repeated administration can produce cumulative GH/IGF-1 stimulation. Serum IGF-1 may remain elevated beyond the final administration, depending on the exposure pattern.

Important Limitation: No human study has established that cycling prevents receptor desensitization, protects pituitary function, improves body composition, or reduces long-term adverse effects.

CJC-1295 with DAC is frequently discussed alongside other experimental peptides and hormones involved in the GH/IGF-1 axis. Although combinations involving different GH-related receptors may have a mechanistic rationale, controlled human studies have not established the safety or effectiveness of common CJC-1295 DAC stacks.

Research Perspective: CJC-1295 with DAC produces sustained GH/IGF-1 stimulation on its own. Adding other growth hormone secretagogues may increase cumulative endocrine exposure without demonstrated additional clinical benefits.

Important Distinction: The combination of CJC-1295 without DAC and ipamorelin should not be treated as equivalent to CJC-1295 with DAC and ipamorelin. The albumin-binding component substantially changes duration and exposure.

Short-term human clinical trials provide direct safety data for CJC-1295 with DAC, but long-term safety remains unknown. The most frequently observed adverse effects involved injection-site reactions, headaches, gastrointestinal symptoms, and systemic vasodilatory responses. Higher doses generally produced more frequent adverse events.

Important Phase 1 Safety Finding: In the initial single-dose study, adverse events were reported in 33 of 35 treated participants compared with two of seven placebo recipients. Most events were transient, but the overall rate was substantial.

Phase 2 Safety Event: A participant in the subsequently terminated HIV-associated visceral-obesity trial reportedly died following an acute myocardial infarction after repeated CJC-1295 exposure. The attending physician attributed the event to underlying coronary artery disease and plaque rupture, but publicly available information is insufficient to independently establish or exclude a causal contribution from the drug.

Long-Term Safety Limitation: Early Phase 1 trials were short and included relatively few participants. The absence of treatment-related deaths in those initial studies does not establish safety during months or years of repeated administration.

FDA Safety Position: The FDA has identified potential significant risks associated with CJC-1295-related substances, including immunogenicity, peptide impurities, increased heart rate, and systemic vasodilatory reactions.

Research Perspective: CJC-1295 with DAC has demonstrated endocrine activity in humans, but its sustained hormonal effects and substantial rates of certain short-term adverse events make assumptions of long-term safety inappropriate.

CJC-1295 with DAC has not completed sufficient clinical development to establish a formal FDA-approved contraindication profile. Its prolonged stimulation of the GH/IGF-1 axis creates several important medical concerns, particularly in individuals with metabolic, cardiovascular, or endocrine disorders.

• Active Cancer: GH and IGF-1 participate in cellular proliferation and growth signaling. Prolonged experimental stimulation warrants particular caution in individuals with malignancy.
• Pregnancy and Breastfeeding: Reproductive, fetal-development, and lactation safety have not been established.
• Diabetes / Insulin Resistance: Increased GH exposure can reduce insulin sensitivity and potentially worsen glucose regulation.
• Elevated IGF-1 / Acromegaly: Additional GH stimulation may be inappropriate in individuals with excessive GH or IGF-1 activity.
• Pituitary Disorders: The compound's effects depend on pituitary function, and its safety in individuals with pituitary tumors or endocrine abnormalities is unknown.
• Heart Failure / Significant Edema: GH-related fluid retention may complicate cardiovascular conditions.
• Uncontrolled Hypertension: Vasodilatory responses and possible fluid-related effects create additional cardiovascular uncertainties.
• Cardiac Arrhythmias / Coronary Disease: Reported heart-rate changes and the unresolved Phase 2 safety event warrant particular caution.
• Obstructive Sleep Apnea: Excessive GH activity can affect soft tissues and fluid distribution, potentially worsening sleep-disordered breathing.
• Kidney Disease: Fluid balance and long-term renal safety have not been adequately evaluated.
• Thyroid Disorders: GH signaling can influence thyroid hormone metabolism, and interactions with thyroid treatment remain insufficiently characterized.
• Diabetes Medications: Changes in insulin sensitivity may complicate management with insulin or other glucose-lowering drugs.
• Concurrent Growth Hormone Secretagogues: Combining multiple GH-active compounds may increase cumulative endocrine exposure.
• Competitive Athletics: CJC-1295 is prohibited under WADA Section S2 for growth hormone-releasing factors.
• Unregulated Products: Research-market products may contain incorrect concentrations, the wrong DAC variant, peptide impurities, or microbial contamination.

Regulatory Caution: CJC-1295 with DAC is not FDA-approved for growth hormone deficiency, visceral fat reduction, muscle growth, recovery, or anti-aging. The FDA has identified potential significant safety concerns with CJC-1295-related substances.

Important Distinction: Some precautions are based on the established physiology of GH and IGF-1 rather than adverse outcomes conclusively demonstrated with CJC-1295. However, the reported cardiovascular reactions and the termination of the Phase 2 program are directly relevant to assessing the compound's risks.

Medical Consideration: Suspected GH deficiency requires specialist endocrine evaluation. A medication that stimulates the pituitary may not produce the intended response in someone with significant pituitary dysfunction.

Human clinical research involving CJC-1295 with DAC has focused primarily on circulating GH and IGF-1 concentrations. Future studies of prolonged exposure would also require evaluation of glucose regulation, cardiovascular function, body composition, and adverse effects.

Research Consideration: IGF-1 is generally more stable over time than a random GH measurement because growth hormone is naturally released in pulses. However, sustained IGF-1 elevation does not establish improved health or physical performance.

Body Composition Consideration: GH-related fluid retention can influence measured lean mass. Strength testing and functional outcomes are important for distinguishing genuine improvements in muscle performance from changes in tissue water.

Important Limitation: Normal blood glucose, IGF-1, and other laboratory measurements cannot independently establish the safety of CJC-1295 with DAC. No monitoring panel or testing interval has been validated for its long-term experimental use.